Treatment of deep venous thrombosis in pregnant women

Acta Obstetricia et Gynecologica Scandinavica

Volumn 87, Issue 11, 2008, Pages 1248-1251

  Lykke, Jacob A ^a,b   Grønlykke, Thor ^a   Langhoff Roos, Jens ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Deep venous thrombosis; Low molecular weight heparin; Pregnancy; Treatment

Indexed keywords

BLOOD CLOTTING FACTOR 10A; TINZAPARIN;

ADULT; ARTICLE; BLOOD CLOT LYSIS; BLOOD SAMPLING; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; DOSE RESPONSE; FEMALE; HUMAN; PREGNANCY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; FEMALE; FIBRINOLYTIC AGENTS; GESTATIONAL AGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PARITY; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREGNANCY OUTCOME; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 56649118677     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1080/00016340802449118     Document Type: Article

References (13)

1. Voke J, Keidan J, Pavord S, Spencer NH, Hunt BJ. The management of antenatal venous thromboembolism in the UK and Ireland: a prospective multicentre observational survey. Br J Haematol. 2007;139:545-58.
2. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005;106:401-7.
3. Hirsh J,Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119(1):64S-94.
4. Kher A, Bauersachs R, Nielsen JD. The management of thrombosis in pregnancy: role of low-molecular-weight heparin. Thromb Haemost. 2007;97:505-13.
5. Norris LA, Bonnar J, Smith MP, Steer PJ, Savidge G. Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. A pharmacokinetic study. Thromb Haemost. 2004;92:791-6.
6. Greer I, Hunt BJ. Low molecular weight heparin in pregnancy: current issues. Br J Haematol. 2005;128:593-601.
7. Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3):627S-44.
8. Cheer SM, Dunn CJ, Foster R. Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease. Drugs. 2004;64:1479-502.
9. Jacobsen AF, Qvigstad E, Sandset PM. Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy. BJOG. 2003;110:139-44.
10. Fareed J, Hoppensteadt D, Schultz C, Ma Q, Kujawski MF, Neville B, et al. Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile. Curr Pharm Des. 2004;10:983-99.
11. Greer I, Thomson AJ. Thromboembolic disease in pregnancy and the puerperium: acute management, (RCOG Green-Top Guideline No. 28). London, UK: RCOG; 2007 (www.rcog. org.uk/index.asp? PageID =533).
12. Breddin HK, Kadziola Z, Scully M, Nakov R, Misselwitz F, Kakkar VV. Risk factors and coagulation parameters in relationship to phlebographic response and clinical outcome in the treatment of acute deep vein thrombosis. Thromb Haemost. 2003;89:272-7.
13. Van Dreden P, Grosley M, Cost H. Total and free levels of tissue factor pathway inhibitor: a risk factor in patients with factor V Leiden? Blood Coagul Fibrinolysis. 1999;10:115-6.